Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise for Long-Term control of cushing syndrome

NCT ID NCT03604198

Ongoing Disease control Sponsor: Corcept Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the long-term safety of relacorilant, a drug for people with Cushing syndrome. It includes 125 adults who previously completed a relacorilant study and may benefit from continued treatment. Researchers will track side effects over time to see if the drug is safe for extended use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
relacorilant
What this could lead to
If successful, this could provide a long-term treatment option for managing Cushing syndrome symptoms.
What could go wrong
This is an early-phase extension study focused on safety, not effectiveness. It may not lead to a new treatment, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUSHING SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ACTH-dependent Cushing syndrome adrenal carcinoma adrenal cortex neoplasm Cushing syndrome ectopic ACTH secretion syndrome hypertensive disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUSHING SYNDROME

Contacts and locations

Locations

  • Site 1

    Indianapolis, Indiana, 46202, United States

  • Site 10

    Atlanta, Georgia, 30318, United States

  • Site 11

    Dallas, Texas, 75390, United States

  • Site 12

    Houston, Texas, 77079, United States

  • Site 13

    Fall River, Massachusetts, 02721, United States

  • Site 14

    Vienna, 1090, Austria

  • Site 16

    Munich, Germany

  • Site 17

    Madrid, 28007, Spain

  • Site 18

    Girona, Spain

  • Site 19

    Seville, Spain

  • Site 2

    Pittsburgh, Pennsylvania, 15212, United States

  • Site 20

    Ramat Gan, 5265601, Israel

  • Site 21

    Naples, 80131, Italy

  • Site 24

    New York, New York, 10021, United States

  • Site 25

    Milan, 20145, Italy

  • Site 27

    Baltimore, Maryland, 21287, United States

  • Site 28

    Bucharest, 11863, Romania

  • Site 29

    Tel Aviv, 64239, Israel

  • Site 3

    St Louis, Missouri, 63110, United States

  • Site 31

    Bucharest, 10825, Romania

  • Site 32

    Fort Worth, Texas, 76132, United States

  • Site 33

    Rotterdam, 3015 GD, Netherlands

  • Site 34

    Jackson, Mississippi, 39202, United States

  • Site 35

    Stanford, California, 94305, United States

  • Site 36

    Rochester, Minnesota, 55905, United States

  • Site 37

    Bucharest, 050474, Romania

  • Site 38

    Málaga, 29006, Spain

  • Site 39

    Torrance, California, 90502, United States

  • Site 4

    Wilmington, North Carolina, 28401, United States

  • Site 40

    Ancona, 60126, Italy

  • Site 42

    Würzburg, 97080, Germany

  • Site 43

    Cleveland, Ohio, 44195, United States

  • Site 44

    Messina, 98125, Italy

  • Site 45

    Lublin, 20412, Poland

  • Site 46

    Pittsburgh, Pennsylvania, 15213, United States

  • Site 47

    Krakow, 30-688, Poland

  • Site 48

    Padova, 35128, Italy

  • Site 49

    Phoenix, Arizona, 85013, United States

  • Site 5

    Metairie, Louisiana, 70006, United States

  • Site 50

    Miami, Florida, 33136, United States

  • Site 51

    Nova Scotia, Canada

  • Site 52

    Torino, Italy

  • Site 53

    Alicante, Spain

  • Site 55

    Reno, Nevada, 89511, United States

  • Site 6

    Albany, New York, 12206, United States

  • Site 7

    El Paso, Texas, 79935, United States

  • Site 8

    Ann Arbor, Michigan, 48109, United States

  • Site 9

    Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.